Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTP001 in idiopathic pulmonary fibrosis
NCT05497284Phase 2Terminated
- Sponsor
- Novartis
- Start
- Nov 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing LTP001 with Placebo (2 arms). Primary endpoint: Change From Baseline to End of Treatment Epoch in Forced Vital Capacity Expressed in Percent Predicted at 26 weeks. Started Nov 2022; status: terminated.
02
Drugs
LTP001
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05497284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05497284.